Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.

Boston-based biotech Avalyn Pharma is the latest to hop on the IPO train, filing to list on the Nasdaq and raise funds for ...

There seems to be a strong exposure-response relationship between nerandomilast and the preservation of FVC in patients with PPF and IPF.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.

Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent ...

Single drugs targeting single biological pathways are insufficient for complex diseases,” Remedy Cell Ltd. CEO Ayelet Dilion Mashiah told BioWorld. Remedy is taking a secretome-based approach to treat ...

Avalyn Pharma (AVLN) stock will be in focus as the company files for a Nasdaq IPO to fund clinical studies for its inhaled ...

Underwriters were given a 30-day option to purchase up to 1.74 million additional shares. ・Trevi is currently developing Haduvio, its treatment for chronic cough in patients with idiopathic pulmonary ...

The Pulmonary Fibrosis Foundation (PFF) today announced its PFF Walk 2026 schedule as the organization celebrates the 10 (th) season of the national fundraising program, which has raised more than $7.